CAL-101 (Idelalisib): Mechanism of Action

CAL-101 (Idelalisib) MOA:Targeting PI3Kδ/BCR Signaling Pathway for B-Cell Malignancies

🎯 check CAL-101 (Idelalisib) product page

CAL-101 (Idelalisib) is a potent, selective PI3Kδ inhibitor. It affects the PI3K/AKT/mTOR signaling pathway by binding to the kinase ATP-binding cleft and reducing AKT phosphorylation, effectively inhibiting tumor cell proliferation and promoting apoptosis in hematological malignancies.

Primary Applications and Mechanism of Action